These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21502062)

  • 1. Importance of early characterization of physicochemical properties in developing high-dose intravenous infusion regimens for poorly water-soluble compounds.
    Jain A; Zheng W; Garad S; Weaver M; Panicucci R
    PDA J Pharm Sci Technol; 2010; 64(6):517-26. PubMed ID: 21502062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
    Li S; Pollock-Dove C; Dong LC; Chen J; Creasey AA; Dai WG
    Mol Pharm; 2012 May; 9(5):1100-8. PubMed ID: 22376012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y; Porter W; Merdan T; Li LC
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Screening Methods To Assess the Potential of In Vivo Precipitation of Injectable Formulations upon Intravenous Administration.
    Sheth AR
    PDA J Pharm Sci Technol; 2011; 65(1):71-80. PubMed ID: 21414942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing.
    Eichenbaum G; Zhou J; De Smedt A; De Jonghe S; Looszova A; Arien T; Van Goethem F; Vervoort I; Shukla U; Lammens L
    J Pharmacol Toxicol Methods; 2013; 68(3):394-406. PubMed ID: 23933112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.
    Mortko CJ; Sheth AR; Variankaval N; Li L; Farrer BT
    J Pharm Sci; 2010 Dec; 99(12):4973-81. PubMed ID: 20821397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro modeling of intravenous drug precipitation by the optical spatial precipitation analyzer (OSPREY).
    Radosevich AJ; Martin RL; Buck WR; Hicks L; Wilsey A; Pan JY
    Int J Pharm; 2023 Apr; 636():122842. PubMed ID: 36925024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat.
    Banfor PN; Gintant GA; Lipari JM; Zocharski PD
    J Pharmacol Toxicol Methods; 2016; 82():62-67. PubMed ID: 27432021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
    Bittner B; Mountfield RJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):59-71. PubMed ID: 11865674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
    Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
    J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed study of precipitation of a poorly water soluble test compound using methodologies as in activity and solubility screening - mixing and automation effects.
    Gillespie C; Kennedy AR; Edwards D; Dowden L; Daublain P; Halling P
    Comb Chem High Throughput Screen; 2013 Sep; 16(8):636-43. PubMed ID: 23713459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.
    Ban K; Sonohara R; Yoshida M; Sako K; Uchida S; Namiki N
    PDA J Pharm Sci Technol; 2013; 67(4):336-53. PubMed ID: 23872444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-Based Formulations Can Enable the Model Poorly Water-Soluble Weakly Basic Drug Cinnarizine To Precipitate in an Amorphous-Salt Form During In Vitro Digestion.
    Khan J; Rades T; Boyd BJ
    Mol Pharm; 2016 Nov; 13(11):3783-3793. PubMed ID: 27631273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro prediction of bioavailability following extravascular injection of poorly soluble drugs: an insight into clinical failure and the role of delivery systems.
    Wu Z; Hassan D; Shaw JP
    J Pharm Pharmacol; 2013 Oct; 65(10):1429-39. PubMed ID: 24028610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound.
    Sigfridsson K; Björkman JA; Skantze P; Zachrisson H
    J Pharm Sci; 2011 Jun; 100(6):2194-202. PubMed ID: 21491443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs.
    Rogers TL; Gillespie IB; Hitt JE; Fransen KL; Crowl CA; Tucker CJ; Kupperblatt GB; Becker JN; Wilson DL; Todd C; Broomall CF; Evans JC; Elder EJ
    Pharm Res; 2004 Nov; 21(11):2048-57. PubMed ID: 15587927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical Formulation Development of an in situ Meglumine Salt of AZD5991: A Novel Macrocyclic Mcl-1 Inhibitor.
    Yang W; Cook S; Wu D
    Pharm Res; 2023 Apr; 40(4):977-988. PubMed ID: 37012536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.